Arthneeti
IH

Influx Healthtech Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Influx Healthtech Ltd Q1 FY26 Results & Presentation Highlights: Revenue ₹104.9 Cr, PAT ₹13.4 Cr

Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹280
Market cap₹634 Cr
P/E30.9
Updated24 Sept 2026
Read4 min read

Based on Influx Healthtech Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). EBITDA for FY25: ₹20.6 crores, a 22% YoY increase (Page 4) - EBITDA Margin FY25: 19.6%, up 269 bps from FY24 (Page 28) - Profit after Tax (PAT) for FY25: ₹13.4 crores, a 20% YoY increase (Pages 4, 28) - PAT Margin FY25: 12.8%, up 165 bps from FY24 (Page 28) - Operating margin (EBITDA margin) explicitly reported as 19.6% for FY25 (Pages 4, 28) - The presentation does not state any explicit forward-looking margin outlook beyond the reported FY25 results.

From Influx Healthtech Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26).
  • Revenue split FY25: Nutraceuticals (₹94.0 cr, 90%), Cosmetics (₹6.4 cr, 6%), Ayurvedic (₹3.2 cr, 3%), Others (₹1.2 cr, 1%) (Page 5).
  • Product portfolio expanded by 6% to 3,559 products in FY25 (Page 4).
  • Highest annual revenue recorded in FY25, indicating growth momentum (Page 4).
  • No explicit quarterly revenue or volume figures are provided.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Influx Healthtech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Planned capacity expansion to increase overall capacity by 2.5x post utilization of IPO proceeds (Page 16). - ₹23 crores investment to establish a new manufacturing facility under the nutraceutical division on a 3,204 mt2 site (Page 16). - ₹12 crores planned for setting up a manufacturing facility under the veterinary food division on a 1,350 mt2 site (Page 16). - ₹3 crores capital expenditure planned for procuring machinery to enhance manufacturing capacity in homecare and cosmetic divisions (Page 16). - Capacity utilization prior to IPO proceeds: • Nutraceuticals: 93% • Cosmetics & Ayurvedic: 90% • Pet supplements & Homecare: 66% (Page 16). - Expanded tablet capacity to 1,230 kg/day; doubled liquid & sachet throughput to 48,000 bottles & 98,000 sachets per shift (Page 17).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Influx Healthtech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report any figures or details regarding order book, order inflow, or pending orders. Based on the content provided: - No specific mention of order book size or value. - No data or commentary on order inflow rates or recent new orders. - No details about pending or backlog orders. The focus of the presentation is primarily on financial performance, revenue growth, capacity expansion, product portfolio, client base, and strategic initiatives, but it does not disclose or discuss order book or order inflow metrics.

Continue your research

What Influx Healthtech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • NGL Fine Chem Ltd (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY26 investor presentation — and how it ranks a

  • Shree Ganesh Remedies Ltd (Q1 FY26)

    Q1FY26 Revenue from Operations: ₹24.67 crores . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY26 investor presentation — and how it

  • Anuh Pharma Ltd (Q1 FY26)

    Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. Key investor presentation takeaways from Anuh Pharma

  • Bharat Parenterals Ltd (Q1 FY26)

    Q1 FY 2026 Revenue from Operations (Consolidated):** ₹116.00 crore, up 25.4% YoY from ₹92.51 crore in Q1 FY 2025 (Page 26). Key investor presentation takeaways

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Influx Healthtech Ltd Q1 FY26 results?

FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). EBITDA for FY25: ₹20.6 crores, a 22% YoY increase (Page 4) - EBITDA Margin FY25: 19.6%, up 269 bps from FY24 (Page 28) - Profit after Tax (PAT) for FY25: ₹13.4 crores, a 20% YoY increase (Pages 4, 28) - PAT Margin FY25: 12.8%, up 165 bps from FY24 (Page 28) - Operating margin (EBITDA margin) explicitly reported as 19.6% for FY25 (Pages 4, 28) - The presentation does not state any explicit forward-looking margin outlook beyond the reported FY25 results.

What is Influx Healthtech Ltd share price analysis?

Influx Healthtech Ltd currently shows a neutral. The stock trades at a P/E of 30.9 with a market cap of ₹634 Cr. Investors should review the full earnings analysis for detailed insights.

Is Influx Healthtech Ltd planning capital expenditure?

Planned capacity expansion to increase overall capacity by 2.5x post utilization of IPO proceeds (Page 16).

Keep Influx Healthtech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.